About Proteintech Group
Founded in 2001 by scientists involved in biomedical research, Proteintech develops research reagents that support the detection, characterisation and analysis of proteins across a wide range of life science disciplines. Its expertise spans antibody development, recombinant antibody generation, immunoassays, cytokines, growth factors and nanobody-based technologies. Proteintech applies extensive validation strategies, including genetic knockdown and knockout controls, to support reproducible experimental workflows. Its products are used in applications such as western blotting, immunohistochemistry, immunofluorescence, flow cytometry, ELISA, immunoprecipitation and chromatin immunoprecipitation, serving research areas including cancer biology, immunology, neuroscience, stem cell biology, metabolism, cell signalling and gene and cell therapy.
The company’s portfolio includes primary and secondary antibodies, recombinant monoclonal antibodies generated using its ABCE™ B-cell cloning and engineering platform, ELISA kits, matched antibody pairs, magnetic cell separation systems, research- and cGMP-grade cytokines and growth factors, and specialised nanobody-based reagents. Product families such as Uni-rAb™, HumanKine®, Nano-Traps, Chromobodies and the Spot-Tag system support protein analysis, cell biology, imaging, target validation and translational research workflows.
Europa Biosite’s subsidiaries distribute for Proteintech in Belgium, Luxembourg and the Netherlands.